The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

MLN9708 in Relapsed Multiple Myeloma Not Refractory to Bortezomib

Shaji K. Kumar, MD
Published Online: 9:31 PM, Mon December 9, 2013
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.

Clinical Pearls

  • 16% of patients had a pre-specified response (minimum minor response by end of Cycle 2 or partial response by end of Cycle 4)
  • 35% of patients had partial response or better under the approach of receiving MLN9708 alone and adding dexamethasone if it did not work well
  • The most common side effects in this trial (fatigue, drop in platelet counts, nausea, and diarrhea) were well managed

<<< Back to the conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.